AMBIRIX

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Lithuania, Netherlands, Poland, United Kingdom

Active ingredients

The drug AMBIRIX contains a combination of these active pharmaceutical ingredients (APIs):

1 Hepatitis A, inactivated vaccine

Inactivated virus of a strain which was originally derived by further serial passage of a proven attenuated strain. The virus is grown, harvested, highly purified, formalin inactivated, and then adsorbed onto amorphous aluminum hydroxyphosphate sulphate. Read about Hepatitis A, inactivated vaccine

2 Hepatitis B, purified antigen

Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer. Read about Hepatitis B, purified antigen

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AMBIRIX Suspension for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07BC20	Combinations	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1208922, 1208933, 1208944
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 129520
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1027357, 1027358, 1027359, 1027360, 1027361
Country: NL	Z-Index G-Standaard	Identifier(s): 14816288
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 48933
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100127298